

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7383859

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CAFA THERAPEUTICS LIMITED	01/26/2022
RECEIVING PARTY DATA	
Name:	CRAGE MEDICAL CO., LIMITED
Street Address:	RM12, 20/F, HO KING COMM CTR, 2-16 FAYUEN ST, MONGKOK
City:	KOWLOON, HONGKONG
State/Country:	CHINA
PROPERTY NUMBERS Total: 6	
Property Type	Number
Application Number:	16765100
Application Number:	15754076
Application Number:	15750271
Application Number:	16331786
Application Number:	15746711
Application Number:	17182956
CORRESPONDENCE DATA	
Fax Number:	(612)455-3801
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6124553800
Email:	ycottle@hsml.com
Correspondent Name:	HAMRE, SCHUMANN, MUELLER & LARSON, P.C.
Address Line 1:	45 SOUTH SEVENTH STREET
Address Line 2:	SUITE 2700
Address Line 4:	MINNEAPOLIS, MINNESOTA 55402
ATTORNEY DOCKET NUMBER:	ASSIGNMENT_CAFA TO CRAGE
NAME OF SUBMITTER:	BRYAN A. WONG
SIGNATURE:	/bryan a. wong/
DATE SIGNED:	06/15/2022
Total Attachments: 4	

source=Assignment_from CAFA to CRAGE#page1.tif
source=Assignment_from CAFA to CRAGE#page2.tif
source=Assignment_from CAFA to CRAGE#page3.tif
source=Assignment_from CAFA to CRAGE#page4.tif

ASSIGNMENT OF PATENTS**Parties:**

- (1) **CAFA THERAPEUTICS LIMITED**, a corporation organized under the laws of the country of Ireland with a place of business at 2/3 Exchange Place, IFSC, Dublin, Ireland D01 AE27 (the '**Assignor**'); and
- (2) **CRAGE medical Co., Limited**, a corporation organized under the law of Hong Kong with an address at RM12, 20/F, Ho King Comm CTR, 2-16 FaYuen ST, Mongkok Kowloon, Hong Kong, China (the '**Assignee**'); and

Together the '**parties**' or each a '**party**' as the context may indicate.

Whereas:

The Assignor is the owner of the inventions (the '**Inventions**'), which are the subject matter of the European patents and patent applications set out in the schedule to this assignment (the '**Patents**').

IT IS AGREED as follows:**1. Assignment**

The Assignor hereby assigns to the Assignee absolutely all of its right, title and interest in, to and arising from the Inventions and the Patents and the Assignee hereby accepts such assignment and transfer for all countries designated, such that the Assignee is hereafter the proprietor of the Inventions and the Patents, including (without limitation):

- (a) In respect of any and each application in the Patents:
 - (i) the right to claim priority from the Patents;
 - (ii) the right to file and prosecute national and regional applications in any country or territory in the world linked to the Patents, and the rights to all matter contained in such applications (the '**Further Applications**'); and
 - (iii) the right to file and prosecute divisional applications, continuations and continuations-in-part of the Patents and all Further Applications (the '**Divisional Applications**'); and
 - (iv) the absolute entitlement to any patents granted pursuant to the Patents, Further Applications and Divisional Applications for their full period, including any re-issues, re-examinations renewals, extensions and Supplementary Protection Certificates; and
- (b) The right to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the Inventions, the Patents and any patents granted on any of the applications filed as aforesaid in sub-clause (a), whether occurring before, on or after the date of this Assignment.

2. Further assurance


At the Assignee's expense, the Assignor will promptly execute and deliver such documents and perform such acts as may be required for the purpose of giving full effect to this Assignment.

3. Counterparts

This Assignment may be executed in any number of counterparts, each of which when executed will constitute a duplicate original, but all the counterparts will together constitute the one Assignment.

This Assignment has been entered into on the final signature date below.

Signed by Huamao WANG (print name), director or authorised representative, for and on behalf of **CAFA THERAPEUTICS LIMITED**



Title: Company Secretary
Signature of director or authorised representative

Date: January 26, 2022

Signed by Zongai LI (print name), director or authorised representative, for and on behalf of **CRAGE medical Co., Limited**



Title: Director
Signature of director or authorised representative

Date: January 26, 2022

Schedule: The Patents

Country Code	Application number	Filing date	Title/ Invention
CA	3050835	January 23, 2018	BCMA-TARGETING ANTIBODY AND USE THEREOF
CA	3100446	May 15, 2019	GENETICALLY ENGINEERED CELL AND APPLICATION THEREOF
CA	2996060	August 22, 2016	FULLY HUMAN ANTI-MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN
CA	2994751	August 2, 2016	ANTIBODY AGAINST GLYPICAN-3 AND APPLICATION THEREOF
CA	3030257	July 10, 2017	ANTIBODY FOR ANTI-CLAUDIN 18A2 AND USE THEREOF
CA	2993262	July 21, 2016	TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND APPLICATION THEREOF
CA	3117759	October 28, 2019	CLL1-TARGETING ANTIBODY AND APPLICATION THEREOF
US	16/316,331	July 10, 2017	ANTIBODY FOR ANTI-CLAUDIN 18A2 AND USE THEREOF
US	17/395,223	July 10, 2017	ANTIBODY FOR ANTI-CLAUDIN 18A2 AND USE THEREOF
US	16/765,100	November 16, 2018	BINDING UNIT TARGETING FIBROBLAST ACTIVATION PROTEIN α AND APPLICATION THEREOF
US	15/754,076	August 22, 2016	FULLY HUMAN ANTI-MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN
US	15/750,271	August 2, 2016	ANTIBODY AGAINST GLYPICAN-3 AND APPLICATION THEREOF
US	16/331,786	July 6, 2017	FUSION PROTEIN AND APPLICATIONS THEREOF
US	15/746,711	July 21, 2016	TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND APPLICATION THEREOF
US	17/182,956	July 21, 2016	TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND APPLICATION THEREOF
US	15/322,033	June 26, 2015	TIME AND SPACE ADJUSTABLE SYSTEM FOR INHIBITING PATHOLOGICAL TARGET CELLS
US	15/532,965	November 30, 2015	GPC3 AND ASGPR1 DOUBLE-TARGETED TRANSGENIC IMMUNE EFFECTOR CELL AND USE THEREOF
US	17/281,372	September 29, 2019	COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPY DRUGS
US	16/963,095	January 21, 2019	SYNNOTCH RECEPTOR-REGULATED EXPRESSION OF IL12
US	17/427,780	February 2, 2020	TCR FUSION PROTEIN AND CELL EXPRESSING TCR FUSION PROTEIN
US	16/479,365	January 23, 2018	BCMA-TARGETING ANTIBODY AND USE THEREOF
US	17/288,189	October 28, 2019	CLL1-TARGETING ANTIBODY AND APPLICATION THEREOF
US	17/413,892	December 13, 2018	IMMUNE EFFECTOR CELL TARGETING GPC3 AND APPLICATION THEREOF
US	16/645,247	September 7, 2018	GENETICALLY ENGINEERED T CELL AND APPLICATION THEREOF

US	17/055,470	May 15, 2019	GENETICALLY ENGINEERED CELL AND APPLICATION THEREOF
US	16/469,091	December 13, 2017	ANTI-CD19 HUMANIZED ANTIBODY AND IMMUNE EFFECTOR CELL TARGETING CD19
US	17/052,425	April 30, 2019	IMMUNE EFFECTOR CELL AND USE THEREOF
US	16/979,102	March 8, 2019	METHOD AND COMPOSITION FOR TREATING TUMORS
EP	19803938.0	May 15, 2019	GENETICALLY ENGINEERED CELL AND APPLICATION THEREOF
EP	18854823.4	September 7, 2018	GENETICALLY ENGINEERED T CELL AND APPLICATION THEREOF
EP	15865161.2	November 30, 2015	GPC3 AND ASGPR1 DOUBLE-TARGETED TRANSGENIC IMMUNE EFFECTOR CELL AND USE THEREOF
EP	19741277.8	January 21, 2019	SYNNOTCH RECEPTOR-REGULATED EXPRESSION OF IL12
EP	18878002.7	November 16, 2018	BINDING UNIT TARGETING FIBROBLAST ACTIVATION PROTEIN α AND APPLICATION THEREOF
EP	17823694.9	July 10, 2017	ANTIBODY FOR ANTI-CLAUDIN 18A2 AND USE THEREOF
EP	20749765.2	February 2, 2020	TCR FUSION PROTEIN AND CELL EXPRESSING TCR FUSION PROTEIN
EP	19877290.7	October 28, 2019	CLL1-TARGETING ANTIBODY AND APPLICATION THEREOF
EP	18943085.3	December 13, 2018	IMMUNE EFFECTOR CELL TARGETING GPC3 AND APPLICATION THEREOF
EP	19797057.7	April 30, 2019	IMMUNE EFFECTOR CELL AND USE THEREOF
EP	19763391.0	March 8, 2019	METHOD AND COMPOSITION FOR TREATING TUMORS